BODI Bodisen

RNS Number:0990P
Bodisen Biotech Inc
08 January 2007



               Bodisen Biotech, Inc. ("Bodisen" or the "Company")



          Bodisen Biotech Receives Preliminary Determination from Amex





Bodisen Biotech, Inc. (AMEX:BBC, London AIM:BODI, website: www.bodisen.com),
today announced that on January 4, 2007 it received a letter from the American
Stock Exchange, LLC ("Amex") indicating that the Amex has determined that the
Company has made a reasonable demonstration of its ability to regain compliance
with continued listing standards by no later than the timely filing of the
Company's Annual Report on Form 10-K for the period ended December 31, 2006 or
April 17, 2007 ("Plan Period End Date").  As stated previously, the Amex has
determined that the Company is not in compliance with certain Amex continued
listing standards.  The Company's securities will continue to be listed on the
Amex during this period pursuant to an extension.



Enquiries:



Charles Stanley Securities (Nominated Adviser)

Rick Thompson / Philip Davies - 0207 149 6000







About Bodisen Biotech, Inc.

Bodisen Biotech Inc. is a leading manufacturer of liquid and organic compound
fertilizers, pesticides, insecticides and agricultural raw materials certified
by the Petroleum Chemical Industry Administrative office of China (Chemical
Petroleum Production Administrative Bureau), Shaanxi provincial government and
Chinese government. Ranked the 16th fastest growing company in China by Forbes
China in January 2006, the Company is headquartered in Shaanxi province and is a
Delaware corporation. The Company's environmentally friendly "green'" products
have been proven to improve soil and plant quality, and increase crop yields.





Safe Harbor Statement

This press release may contain forward-looking statements within the meaning of
the 'safe harbor' provisions of the Private Securities Litigation Act of 1995.
These statements are based on the current expectations or beliefs of Bodisen
Biotech, Inc. management and are subject to risks and uncertainties that could
cause actual results to differ materially from those described in the
forward-looking statements.  The potential risks and uncertainties include,
among others, the fact that this statement reflects preliminary findings, that
Bodisen's independent review and the Amex inquiry are ongoing, and that further
review may require adjustments to these statements. Please also note that there
can be no guarantee that the Company's compliance with the Amex letter dated
January 4, 2007 will guarantee its continued listing on the Amex.




                      This information is provided by RNS
            The company news service from the London Stock Exchange
END

MSCSSSFAISWSEDF

Grafico Azioni Bodisen Biotech (LSE:BODI)
Storico
Da Mag 2024 a Giu 2024

Grafico Azioni Bodisen Biotech (LSE:BODI)
Storico
Da Giu 2023 a Giu 2024